QualityStocks would like to highlight Genta, Inc.(OTCBB: GNTA), a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel.
In the company’s news yesterday,
Genta announced that it has added the first patient to a new randomized trial of tesetaxel as initial chemotherapy for women with advanced or recurrent breast cancer.
The company expects to enroll 220 patients for the 12-month, randomized phase 2b study, which will be conducted across 15 sites in the U.S. and Western Europe.
The participating women will not have previously received chemotherapy for metastatic or recurrent disease, though eligible patients who are HER2-negative may have received adjuvant chemotherapy and hormonal therapy.
The study will compare two oral chemotherapy agents; patients will be randomized to one of three treatment groups administered twice per day for 14 consecutive days. The primary endpoint of the trial is overall response rate; secondary endpoints include progression-free survival and safety.
In the previously conducted two phase 2a studies, tesetaxel was generally well-tolerated. In the first study, 13 of 34 patients (38 percent) achieved a major objective response, and 11 patients achieved stable disease, for a disease control rate of 70 percent. In the second trial, 20 of 44 patients (45 percent) achieved major objective responses with a disease-control rate of 82 percent.
“Our preliminary results suggest that tesetaxel may compare favorably with capecitabine across a number of parameters, including response, safety, convenience, and compliance,” Dr. Loretta M. Itri, Genta’s president and chief medical officer stated in the press release. “Genta has now completed two, non-randomized, phase 2a studies comprised of more than 80 patients. The Company has been engaged in extended discussions with regulatory authorities in the U.S. and EU regarding potential registration strategies for tesetaxel in breast cancer. We believe this new study will provide a firm basis for a phase 3 trial design as first-line chemotherapy in this patient population.”
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.